Goldman Sachs’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-3,590,091
| Closed | -$64.6M | – | 5683 |
|
|
2020
Q2 | $64.6M | Buy |
3,590,091
+2,306,912
| +180% | +$32.1M | 0.02% | 778 |
|
|
2020
Q1 | $9.15M | Buy |
1,283,179
+685,231
| +115% | +$8.55M | ﹤0.01% | 2150 |
|
|
2019
Q4 | $14.3M | Sell |
597,948
-499,829
| -46% | -$13.8M | ﹤0.01% | 2146 |
|
|
2019
Q3 | $29.4M | Buy |
1,097,777
+331,724
| +43% | +$9.31M | 0.01% | 1504 |
|
|
2019
Q2 | $20.8M | Sell |
766,053
-42,759
| -5% | -$1.34M | 0.01% | 1827 |
|
|
2019
Q1 | $28.1M | Buy |
808,812
+238,890
| +42% | +$6.89M | 0.01% | 1571 |
|
|
2018
Q4 | $11.1M | Buy |
569,922
+91,576
| +19% | +$1.88M | ﹤0.01% | 2273 |
|
|
2018
Q3 | $12.7M | Buy |
478,346
+58,414
| +14% | +$1.91M | ﹤0.01% | 2269 |
|
|
2018
Q2 | $15.9M | Sell |
419,932
-36,439
| -8% | -$1.39M | ﹤0.01% | 2069 |
|
|
2018
Q1 | $14.9M | Buy |
456,371
+93,739
| +26% | +$4.11M | ﹤0.01% | 2053 |
|
|
2017
Q4 | $17.7M | Sell |
362,632
-69,676
| -16% | -$3.52M | ﹤0.01% | 2028 |
|
|
2017
Q3 | $23.4M | Sell |
432,308
-255,784
| -37% | -$15M | 0.01% | 1858 |
|
|
2017
Q2 | $38.6M | Buy |
688,092
+171,046
| +33% | +$6.85M | 0.01% | 1424 |
|
|
2017
Q1 | $20.3M | Buy |
517,046
+350,240
| +210% | +$11.2M | 0.01% | 1880 |
|
|
2016
Q4 | $3.74M | Sell |
166,806
-662,048
| -80% | -$12.9M | ﹤0.01% | 3305 |
|
|
2016
Q3 | $18.8M | Buy |
828,854
+701,548
| +551% | +$16.5M | 0.01% | 1933 |
|
|
2016
Q2 | $3M | Buy |
127,306
+2,460
| +2% | +$60.7K | ﹤0.01% | 3263 |
|
|
2016
Q1 | $2.55M | Buy |
124,846
+57,307
| +85% | +$1.82M | ﹤0.01% | 3267 |
|
|
2015
Q4 | $3.48M | Sell |
67,539
-26,381
| -28% | -$1.28M | ﹤0.01% | 3161 |
|
|
2015
Q3 | $4M | Buy |
93,920
+68,845
| +275% | +$3.32M | ﹤0.01% | 3081 |
|
|
2015
Q2 | $1.14M | Buy |
25,075
+18,250
| +267% | +$734K | ﹤0.01% | 4418 |
|
|
2015
Q1 | $259K | Sell |
6,825
-11,588
| -63% | -$398K | ﹤0.01% | 5777 |
|
|
2014
Q4 | $521K | Buy |
+18,413
| New | +$512K | ﹤0.01% | 5244 |
|
|
2014
Q3 | – | Sell |
-12,635
| Closed | -$369K | – | 7338 |
|
|
2014
Q2 | $369K | Sell |
12,635
-3,224
| -20% | -$78K | ﹤0.01% | 5592 |
|
|
2014
Q1 | $411K | Sell |
15,859
-18,967
| -54% | -$506K | ﹤0.01% | 5455 |
|
|
2013
Q4 | $897K | Sell |
34,826
-179,399
| -84% | -$4.36M | ﹤0.01% | 4830 |
|
|
2013
Q3 | $5.73M | Sell |
214,225
-1
| -0% | -$24 | ﹤0.01% | 2793 |
|
|
2013
Q2 | $5.26M | Buy |
+214,226
| New | +$4.26M | ﹤0.01% | 2685 |
|
Goldman Sachs's PTLA Position: Q3 2020 in Review
Goldman Sachs sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 3,590,091 shares — an estimated $64.6M sold.
Goldman Sachs first reported a position in PTLA in Q2 2013 and held it in 28 quarters. The position peaked at $64.6M in Q2 2020. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- Goldman Sachs reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Goldman Sachs sold 3,590,091 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $64.6M.
- Goldman Sachs first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 28 quarters.
- Goldman Sachs's Portola Pharmaceuticals, Inc. position peaked at $64.6M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on Goldman Sachs's 13F filing for Q3 2020, filed 13 Nov 2020.